Key result
Treatment with Levosimendan improved left ventricular dysfunction, increased cardiac index, decreased pulmonary vascular resistance, and reduced the frequency and extent of pulmonary hypertension crises.
Why the study?
Does Levosimendan improve cardiac function and reduce pulmonary hypertension crises in an infant with myocardial infarction and refractory pulmonary hypertension?
Case Report (n=1)
Does Levosimendan improve cardiac function and reduce pulmonary hypertension crises in an infant with myocardial infarction and refractory pulmonary hypertension?
Levosimendan may serve as an effective long-term inotropic agent and pulmonary vasodilator in infants with depressed cardiac function and refractory pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for levosimendan in infants with MI and refractory PH; controlled trials needed before adoption.
An infant with myocardial infarction due to congenital stenosis of the left coronary artery with consecutive left ventricular dysfunction and mitral regurgitation developed refractory pulmonary hypertension (PHT) and recurrent PHT crises. Catecholamines to support cardiac function, or pulmonary vasodilators like inhaled nitric oxide showed no effect. Treatment with Levosimendan (Simdax), a new inodilator, combining both inotropic and pulmonary vasodilating effects, improved left ventricular dysfunction, increased cardiac index, decreased pulmonary vascular resistance and reduced frequency and extent of the PHT crises. This case may suggest the use of Levosimendan as a long-term inotropic agent and pulmonary vasodilator in children with depressed cardiac function.
No takes yet. Share an insight, caveat, or question.
Yc et al. (2004) conducted a case report in Myocardial infarction with refractory pulmonary hypertension (n=1). Levosimendan vs. Catecholamines and inhaled nitric oxide (prior failed therapies) was evaluated on Left ventricular dysfunction, cardiac index, pulmonary vascular resistance, and pulmonary hypertension crises. Treatment with Levosimendan improved left ventricular dysfunction, increased cardiac index, decreased pulmonary vascular resistance, and reduced the frequency and extent of pulmonary hypertension crises.
Synapse has enriched 10 related papers. Consider them for comparative context: